Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study — Alessandro Vitale (2025) | RDL Network
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Article 2025 en
Authors
AV
Alessandro Vitale
JK
Jung Sun Kim
GC
Giuseppe Cabibbo
Abstract
1 min read
Although patients treated with AB achieved higher OR and PC rates than those treated with LENV, AC remained similarly low, highlighting a potentially worrisome UC phenomenon in real life, also with novel immunotherapy-based combinations.
Pasquale Lombardi, Jung Sun Kim, Giulia Francesca Manfredi, Ciro Celsa, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Nidhi Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei‐Fan Hsu, Brooke Wietharn, Marianna Silletta, Alessandro Parisi, Chun‐Yen Lin, Andrea Dalbeni, Gianluca Masi, Martin Schönlein, Johann von Felden, Fabio Piscaglia, Peter R. Galle, Masatoshi Kudo, Tiziana Pressiani, Lorenza Rimassa, Mario Pirisi, Giuseppe Cabibbo, Hong Jae Chon, David J. Pinato
Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda,
Ciro Celsa, Giuseppe Cabibbo, Thomas U. Marron, Anwaar Saeed, Matthias Pinter, Yi‐Hsiang Huang, A. Pillai, Martin Schoenlein, Johann von Felden, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Hong Jae Chon, Wei‐Fan Hsu, Leonardo Brunetti, Carmine Pinto, Melissa Bersanelli, Alessio Cortellini, D.J. Pinato
Discussion(0)
No comments yet. Be the first to comment.